27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Atreca, Inc. (NASDAQ:BCEL) shares opened for trade Thursday morning at $19.90. The IPO of 7.35 million shares was priced at $17.
Atreca is a biopharma company that uses its platform to discover and develop antibody-based immunotherapies to treat a range of solid tumor types. Unlike the traditional oncology drug discovery approaches, Atreca uses human immune system to lead it to unique antibody-target pairs from patients experiencing a clinically meaningful active immune response against their tumors.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The company's lead product candidate ATRC-101 is a monoclonal antibody, which reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. ATRC-101 has demonstrated robust anti-tumor activity as a single agent in multiple preclinical models.
Atreca generated a loss of $37.94 million in fiscal year 2018, wider than the loss of $27.53 million in the year-ago period. For the third quarter ended March 2019, the loss was $13.58 million.
The stock traded around $16.61 per share at time of publication.
Related Links:
Atreca IPO: What You Need To Know
FDA Approves Edesa's Dermatitis Treatment Study, Shares Up More Than 100%
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.